<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802369</url>
  </required_header>
  <id_info>
    <org_study_id>PMMHRI-BCO.71/2020</org_study_id>
    <nct_id>NCT04802369</nct_id>
  </id_info>
  <brief_title>Factors and Prognostic Significance of Impaired Exercise Tolerance in Women Over 40 With Arterial Hypertension</brief_title>
  <official_title>Factors and Prognostic Significance of Impaired Exercise Tolerance in Women Over 40 With Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Mother Memorial Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polish Mother Memorial Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subject of the study is evaluation of factors affecting to exercise intolerance in&#xD;
      spiroergometry in women over 40 years of age with hypertension and association and&#xD;
      relationship between the parameters of physical performance and prognosis in this group of&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 185 women over 40 years of age hospitalized for arterial hypertension in the Department&#xD;
      of Cardiology will be included in the study, including: the study group who demonstrated&#xD;
      maximal oxygen consumption measured during incremental exercise indexed per kilogram -&#xD;
      VO2max&lt;17 ml/kg/min and a second group who presented VO2max&gt;17 ml/min/kg.Selected prognostic&#xD;
      factors will be analyzed, among others: demographic data of the patient, physical&#xD;
      examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results&#xD;
      of selected laboratory tests, selected electrocardiographic and echocardiographic data,&#xD;
      patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric&#xD;
      study, non-invasive assessment for central arterial pressure waveform analysis and body mass&#xD;
      analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The 185 women over 40 years of age hospitalized for arterial hypertension in the Department of Cardiology will be included in the study, including: the study group who demonstrated maximal oxygen consumption measured during incremental exercise indexed per kilogram - VO2max&lt;17 ml/kg/min and a second group who presented VO2max&gt;17 ml/min/kg.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prognosis in arterial hypertension</measure>
    <time_frame>One year after inclusion in the study</time_frame>
    <description>A telephone interview will be conducted with patients. These will be questions about death, cardiovascular adverse events (myocardial infarction, acute coronary syndrome), occurrence of symptoms of heart failure, diabetes mellitus, atrial fibrillation, necessity performing coronary angiography or re-hospitalization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Identyfication of prognostic factors in VO2max&lt;17 ml/kg/min</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Selected prognostic factors will be analyzed in patients with VO2max&lt;17 ml/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identyfication of prognostic factors in VO2max&gt;17 ml/kg/min</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Selected prognostic factors will be analyzed in patients with VO2max&gt;17 ml/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic tests</intervention_name>
    <description>Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.</description>
    <arm_group_label>Identyfication of prognostic factors in VO2max&lt;17 ml/kg/min</arm_group_label>
    <arm_group_label>Identyfication of prognostic factors in VO2max&gt;17 ml/kg/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age equal to or older than 40 years&#xD;
&#xD;
          -  Arterial hypertension (HA) diagnosed according to the 2018 European Society of&#xD;
             Cardiology (ESC) guidelines of HA [1]&#xD;
&#xD;
          -  Current HA hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hypertension&#xD;
&#xD;
          -  Diagnosis of heart failure or typical symptomatic heart failure&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;50%&#xD;
&#xD;
          -  Documented: hyperandrogenism, hyperestrogenism, insulin resistance, premature ovarian&#xD;
             failure, polycystic ovary syndrome&#xD;
&#xD;
          -  Past myocardial infarction&#xD;
&#xD;
          -  Diagnosis of cardiomyopathy (hypertrophic, dilated, restrictive, peripartum,&#xD;
             arrhythmogenic)&#xD;
&#xD;
          -  Lysosomal storage disorders&#xD;
&#xD;
          -  Stroke, transient ischemic attack, Intracerebral hemorrhage in medical history&#xD;
&#xD;
          -  Severe hyper- and hypothyroidism&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Chronic kidney disease (IV, V stadium according to National Kidney Foundation) and&#xD;
             dialysis treatment&#xD;
&#xD;
          -  Documented neoplastic process&#xD;
&#xD;
          -  The patient's inability to cooperate and/or provide informed consent to participate in&#xD;
             a research&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  Treatment using immunosuppressants, cytostatic drugs, glucocorticosteroids, or&#xD;
             antiretroviral drugs&#xD;
&#xD;
          -  A history of bone marrow transplant or other organ transplant, treatment with blood&#xD;
             products within the last 6 months&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)&#xD;
             carrier or positive for hepatitis B surface antigen (HBSAg) or antibodies to HCV&#xD;
&#xD;
          -  Surgery or serious injury within the last month&#xD;
&#xD;
          -  Patients who did not express their informed consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agata Bielecka-Dabrowa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, PMMHRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Failure Unit; Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940. Erratum in: J Hypertens. 2019 Jan;37(1):226.</citation>
    <PMID>30234752</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>exercise intolerance</keyword>
  <keyword>troponin</keyword>
  <keyword>body mass compartments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

